View Older Stories View More Recent Stories

May 28, 2025 08:31AM Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE
Mar 27, 2025 08:30AM Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
Mar 10, 2025 10:17PM 2seventy bio (TSVT) Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
Mar 10, 2025 10:17PM 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
Mar 4, 2025 01:45AM Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Jan 22, 2025 08:30AM Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
Jan 13, 2025 07:02AM Bristol-Myers Squibb (BMY) and ArsenalBio Achieve Milestone for AB-4000 Series
Jan 13, 2025 07:00AM ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
Dec 23, 2024 06:45AM Bristol-Myers Squibb (BMY) Receives EU Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Col
Dec 23, 2024 06:45AM Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or
Dec 18, 2024 08:45AM Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Nov 15, 2024 08:23AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo plus Yervoy
Nov 15, 2024 08:23AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatc
Nov 15, 2024 06:59AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Repotrectinib
Nov 15, 2024 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
Nov 5, 2024 05:00PM Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Oct 31, 2024 06:59AM Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
Oct 28, 2024 06:59AM Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
Oct 4, 2024 05:59AM Bristol-Myers Squibb (BMY) Reports FDA Approval of Perioperative Treatment of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC
Oct 3, 2024 05:35PM U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Ce
Sep 27, 2024 11:06AM Bristol-Myers Squibb (BMY) Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
Sep 27, 2024 11:06AM Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
Sep 27, 2024 06:54AM PureTech Health Plc (PRTC) -Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Sep 27, 2024 06:02AM Bristol-Myers Squibb (BMY) Announces FDA Approval of COBENFY
Sep 27, 2024 02:00AM PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Sep 26, 2024 11:59PM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Sep 26, 2024 09:05PM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Sep 18, 2024 06:59AM Bristol-Myers Squibb (BMY) Reports New Long-Term Zeposia Data Showing Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Sep 18, 2024 06:59AM New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Sep 15, 2024 08:55AM Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
Sep 12, 2024 06:59AM Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
Sep 10, 2024 05:45PM Bristol Myers Squibb Announces Dividend
Sep 9, 2024 06:59AM Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Sep 6, 2024 07:00AM Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
Sep 1, 2024 03:33AM Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Aug 28, 2024 02:01AM PureTech Health plc – Half-Year Report
Aug 27, 2024 06:59AM Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Aug 26, 2024 06:59AM Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
Aug 21, 2024 07:00AM Bristol-Myers Squibb (BMY) Announces FDA sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
Aug 21, 2024 06:59AM Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
Aug 19, 2024 06:59AM Bristol-Myers Squibb (BMY): EMA Validates Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Aug 19, 2024 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Jul 26, 2024 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
Jul 21, 2024 06:00AM 10 policies if Trump wins and stock implications: Jefferies
Jul 19, 2024 06:59AM Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
Jul 19, 2024 06:59AM Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Ca
Jul 18, 2024 09:15AM Bristol Myers Squibb Reaches Major Milestone in Environmental Sustainability
Jul 8, 2024 06:59AM Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
Jun 28, 2024 03:40PM Bristol Myers Squibb Named to Dow Jones Sustainability Index North America
Jun 24, 2024 05:45AM Bristol-Myers Squibb (BMY) Announces U.S. FDA Accelerated Approval of KRAZATI in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic
View More Recent Stories View Older Stories